In short
This article examines the ongoing clinical trials investigating the use of Sodium 2-Hydroxylinoleate, also known as ABTL0812, in cancer treatment. These trials focus on evaluating the safety, efficacy, and potential benefits of ABTL0812 in various cancer types, including neuroblastoma, solid tumors, and metastatic pancreatic cancer. The studies aim to determine the optimal dosage, assess its effectiveness when combined with other treatments, and explore its impact on patient outcomes.
At a glance
- Drug Name
- ABTL0812 (Sodium 2-Hydroxylinoleate)
- Cancer Types Studied
- Relapsed/refractory neuroblastoma, solid tumors in children, metastatic pancreatic ductal adenocarcinoma
- Administration
- Oral capsules
- Trial Phases
- Phase I/II
- Key Objectives
- Determine recommended Phase 2 dose, evaluate safety and efficacy, assess pharmacokinetics and pharmacodynamics
- Combination Therapies
- FOLFIRINOX (for pancreatic cancer), irinotecan-temozolomide (for neuroblastoma)
- Primary Endpoints
- Dose-limiting toxicities, progression-free survival
- Secondary Endpoints
- Overall survival, objective response rate, quality of life, biomarker analysis
- Patient Age Groups
- Children (1-21 years) for neuroblastoma trials, Adults (18+ years) for pancreatic cancer trial
- Orphan Drug Designation
- Granted (EU/3/15/1485 and EU/3/17/1911)
What is ABTL0812?
ABTL0812 is the code name for a drug called sodium 2-hydroxylinoleate. It's a new type of medication being developed to treat various forms of advanced cancer. This drug is still in the experimental stage, which means it's being tested in clinical trials to determine if it's safe and effective for patients.
How Does It Work?
ABTL0812 is classified as a peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist. This means it activates certain proteins in the body that can help control cancer growth. It's also considered an antineoplastic agent, which is a fancy term for drugs that fight cancer. The exact way ABTL0812 works in the body is still being studied, but researchers believe it may help stop cancer cells from growing and spreading.
What Conditions Does It Treat?
ABTL0812 is being studied for several types of advanced cancers, including:
- Neuroblastoma: A type of cancer that starts in early nerve cells, usually affecting children
- Other solid tumors in children: This includes various types of cancers that form solid masses in the body
- Metastatic pancreatic ductal adenocarcinoma: An advanced form of pancreatic cancer that has spread to other parts of the body
It's important to note that ABTL0812 is being tested in patients whose cancer has either come back after treatment (relapsed) or hasn't responded well to standard treatments (refractory).
Current Clinical Trials
ABTL0812 is currently being studied in several clinical trials:
- A phase I/II trial for children with relapsed or refractory neuroblastoma and other solid tumors
- A phase I/II study combining ABTL0812 with a chemotherapy regimen called FOLFIRINOX for patients with metastatic pancreatic cancer
These trials aim to determine the right dose of ABTL0812, assess its safety, and see how well it works in treating these cancers.
How Is It Administered?
ABTL0812 comes in the form of capsules that are taken by mouth. The exact dosage and schedule depend on the specific clinical trial and the patient's condition. In some studies, ABTL0812 is given alone, while in others, it's combined with other cancer treatments like chemotherapy.
Potential Side Effects
As ABTL0812 is still in clinical trials, all of its potential side effects are not yet known. The trials are designed to carefully monitor patients for any adverse reactions. Common side effects of cancer treatments can include nausea, fatigue, and changes in blood cell counts, but the specific side effects of ABTL0812 will be better understood as more data is collected from the ongoing trials.
Future Prospects
While ABTL0812 shows promise, it's important to remember that it's still in the testing phase. The results of the current clinical trials will help determine if ABTL0812 is effective and safe enough to become an approved treatment for cancer patients. If successful, it could provide a new option for patients with hard-to-treat cancers, especially those who haven't responded well to other treatments.